World Journal of Gastrointestinal Oncology

Papers
(The H4-Index of World Journal of Gastrointestinal Oncology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Young-onset colorectal cancer: A review47
Early-onset colorectal cancer: Current insights and future directions38
Liquid biopsy in cholangiocarcinoma: Current status and future perspectives34
Colorectal cancer screening in the COVID-19 era31
Propofol induces ferroptosis and inhibits malignant phenotypes of gastric cancer cells by regulating miR-125b-5p/STAT3 axis29
Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature27
Nanotechnology and pancreatic cancer management: State of the art and further perspectives24
Small bowel adenocarcinoma: An overview23
Colorectal cancer carcinogenesis: From bench to bedside22
Microbiome and colorectal carcinogenesis: Linked mechanisms and racial differences21
Diverse roles of FOXO family members in gastric cancer21
Radiomics in hepatocellular carcinoma: A state-of-the-art review21
Diagnostic value of four serum exosome microRNAs panel for the detection of colorectal cancer21
Overgrowth of Lactobacillus in gastric cancer20
Regulatory RNAs, microRNA, long-non coding RNA and circular RNA roles in colorectal cancer stem cells20
Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle20
Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives20
Helicobacter pylori infection and other bacteria in pancreatic cancer and autoimmune pancreatitis20
BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs20
Development of artificial intelligence technology in diagnosis, treatment, and prognosis of colorectal cancer19
Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures19
Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma19
0.045788049697876